FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013
Executive Summary
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013.
You may also be interested in...
FDA Aims Neglected Tropical Disease Guidance At Inexperienced Sponsors
Big pharma is not the prime player in the tropical disease area, even as some large firms increase funding.
FDA Aims Neglected Tropical Disease Guidance At Inexperienced Sponsors
Big pharma is not the prime player in the tropical disease area, even as some large firms increase funding.
Paladin’s Impavido Could Set A Price Tag For Priority Review Vouchers
Approval of the leishmaniasis treatment by its December user fee date would give the Canadian sponsor a voucher for a priority review, which it is likely to sell to another company.